hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06383455 id: Observational briefTitle: Effects of Smoking on Clinical and Microbiological Response in Individuals With Periodontitis overallStatus: COMPLETED date: 2018-09-15 date: 2019-02-01 date: 2019-03-01 date: 2024-04-25 date: 2024-04-25 name: Trakya University class: OTHER briefSummary: This study aimed to compare the distribution of subgingival periodontal pathogens following non-surgical periodontal therapy in smoking and non-smoking people with periodontitis. The main question it aims to answer is:
Researchers performed non-surgical periodontal therapy on 48 participants with stage III/IV periodontitis and recorded clinical measurements. They obtained subgingival plaque samples from periodontal pockets at the onset and after four weeks of treatment, determining the level of periodontopathogens using a polymerase chain reaction-based method. conditions: Periodontitis conditions: Smoking Habit conditions: Subgingival Plaque studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 48 type: ACTUAL name: Non-surgical periodontal therapy measure: Change in levels of periodontopathogens in subgingival plaque after non-surgical periodontal therapy in smokers and non-smokers with stage 3/4 periodontitis measure: Change in clinical attachment level (CAL) measure: Change in probing depth (PD) measure: Change in gingival index (GI) scores measure: Change in plaque index (PI) scores measure: Change in Bleeding on Probing (BOP) sex: ALL minimumAge: 35 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Trakya University city: Edirne zip: 22030 country: Turkey lat: 41.67719 lon: 26.55597 hasResults: False
nctId: NCT06383442 id: N202103041 briefTitle: HIIT on Overweight Middle-aged Adults acronym: HIIT overallStatus: COMPLETED date: 2021-05-25 date: 2023-07-31 date: 2023-11-22 date: 2024-04-25 date: 2024-04-25 name: Taipei Medical University class: OTHER briefSummary: 36 middle-aged with overweight adults were divided into three groups: 1. L-HIIT group: the long-interval HIIT group (4 × 4 min Exercise/4 min Rest), 2. M-HIIT group: the medium-interval HIIT group (8 × 2 min Exercise/2 min Rest), 3. Control group: no exercise intervention. All groups carried out the training stage for 8 weeks (three sessions per week) and the detraining stage for 4 weeks in order to investigate the effects induced by different HIIT interventions on inflammation, metabolic adaptation, anti-fatigue and exercise performance, and fat loss. conditions: Overweight or Obesity studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Participants were evenly distributed according to a counterbalanced design and divided into three different groups by the body fat percentage of subjects: 1. L-HIIT group: the long-interval HIIT group (4 × 4 min Exercise/4 min Rest), 2. M-HIIT group: the medium-interval HIIT group (8 × 2 min Exercise /2 min Rest), 3. Control group. Target intensities of each interval bout, exercise and rest (Ex./R.), were 85-90% VO2peak/65-70% VO2peak zones, respectively. primaryPurpose: OTHER masking: NONE count: 36 type: ACTUAL name: L-HIIT name: M-HIIT measure: Aerobic Capacity Test measure: Aerobic Capacity Test measure: Anti-fatigue performance measure: skinfold thickness measure: Body composition_body fat measure: Glucose measure: Triglycerides measure: low-density lipoprotein (LDL) measure: high-density lipoprotein (HDL) measure: creatine kinase (CK) level measure: C-reactive protein (CRP) measure: tumor necrosis factor (TNF)-R1 measure: TNF-R2 sex: ALL minimumAge: 20 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Taipei Medical University city: Taipei zip: 110 country: Taiwan lat: 25.04776 lon: 121.53185 hasResults: False
nctId: NCT06383429 id: P.T-WH-10/2023-521 briefTitle: Relation Between Forward Head Posture and Incidence of Headache in Obese Adults overallStatus: COMPLETED date: 2024-01-01 date: 2024-03-14 date: 2024-04-15 date: 2024-04-25 date: 2024-04-25 name: Ahram Canadian University class: OTHER briefSummary: Cross sectional study to detect relation between forward head posture and headache. We will take information from the patient about:
* Headache disability index conditions: Obese conditions: Headache conditions: Neck Pain studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 40 type: ACTUAL name: forward head posture by using mobile application. And patients will fill out headache disability index. measure: forward head posture measure: BMI measure: headache disability index sex: ALL minimumAge: 20 Years maximumAge: 30 Years stdAges: ADULT facility: Ababa physical therapy center city: Banī Suwayf state: Beni- Suaf zip: 2711860 country: Egypt lat: 29.07441 lon: 31.09785 hasResults: False
nctId: NCT06383416 id: P.T-INT-10/2023-522 briefTitle: Incidence of Headache and Its Effect on Quality of Life in Geriatric Patients With Chronic Neck Pain overallStatus: COMPLETED date: 2024-01-21 date: 2024-03-20 date: 2024-04-20 date: 2024-04-25 date: 2024-04-25 name: Ahram Canadian University class: OTHER briefSummary: cross sectional study to detect the incidence of headache and its effect on quality of life in geriatric patients with chronic neck pain. Patients will fill out quality of life questionnaire and headache disability index. We will take information from the patients about:
* Visual analogue scale of chronic neck pain. Main measures: chronic neck pain will be assessed by visual analogue scale. Patients will fill out quality of life questionnaire and headache disability index. conditions: Geriatric Patients With Neck Pain studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 40 type: ACTUAL name: Neck pain by VAS measure: Visual analogue scale measure: headache disability index measure: SF-36 quality of life questionare sex: ALL minimumAge: 60 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ababa physical therapy center city: Banī Suwayf zip: 2711860 country: Egypt lat: 29.07441 lon: 31.09785 hasResults: False
nctId: NCT06383403 id: CLIN-60190-463 id: 2024-510695-20-00 type: CTIS briefTitle: A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. acronym: ELSPIRE overallStatus: NOT_YET_RECRUITING date: 2024-07-01 date: 2026-06-22 date: 2026-12-21 date: 2024-04-25 date: 2024-04-25 name: Ipsen class: INDUSTRY briefSummary: The participants in this study will have confirmed PBC with inadequate response or intolerance to Ursodeoxycholic acid (UDCA), which is a medication used in the management and treatment of cholestatic liver disease.
They will also be asked to fill in questionnaires. Each participant will be in this study for up to 64 weeks (15 months). conditions: Primary Biliary Cholangitis studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 72 type: ESTIMATED name: Elafibranor name: Placebo measure: Percentage of participants with normalisation of Alkaline Phosphate (ALP) Levels measure: Percentage of participants with normalisation of ALP Levels measure: Change from baseline in ALP levels measure: Percentage of participants with normalisation of ALP Levels and ≥15% decrease from Baseline measure: Percentage of participants with ≥40% decrease from Baseline in ALP Levels measure: Percentage of participants with ALP <0.5 × Upper Limit of Normal (ULN) measure: Changes from baseline in Total Bilirubin (TB) Levels measure: Percentage of participants with TB <0.7 × ULN measure: Percentage of participants with normalisation of ALP and TB <0.7 × ULN measure: Percentage of participants with normalisation of TB and ALP Levels measure: Percentage of participants with complete biochemical response measure: Change from baseline in PBC Worst Itch Numeric Rating Scale (NRS) score measure: Percentage of participants with moderate to severe pruritus at baseline (i.e. score ≥4) with a clinically meaningful response in PBC Worst Itch NRS measure: Change from baseline in 5-D itch score measure: Change from baseline in Patient Global Impression of Severity (PGI-S) scores measure: Patient Global Impression of Change (PGI-C) scores measure: Change from baseline in PBC-40 Quality of Life (QoL) scores measure: Change from baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue Short Form 7a scores measure: Percentage of participants experiencing Treatment- Emergent Adverse Events (TEAEs), treatment- related TEAEs, Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs). measure: Percentage of participants developing clinically significant changes in physical examination measure: Percentage of participants developing clinically significant changes in vital signs measure: Percentage of participants developing clinically significant changes in Electrocardiogram (ECG) Readings measure: Percentage of participants developing clinically significant changes in laboratory parameters sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06383364 id: SHS-Pharm - 1 - 2024 briefTitle: The Effect of a Medication Coordinator on the Quality of Patients Medication Treatment acronym: MEDCOOR overallStatus: ENROLLING_BY_INVITATION date: 2024-05-01 date: 2025-06-01 date: 2025-06-01 date: 2024-04-25 date: 2024-04-25 name: University of Southern Denmark class: OTHER briefSummary: To examine the effect of a Medication Coordinator, who facilitates medication reviews in close collaboration with patients using My Medication Plan to reduce the risk of post-hospital inappropriate medication usage. conditions: Medication Administered in Error studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: HEALTH_SERVICES_RESEARCH masking: SINGLE whoMasked: CARE_PROVIDER count: 140 type: ESTIMATED name: Medication Coordinator measure: Reduction of potentially inappropriate medication according to Potentially Inappropriate Medication List measure: Evaluation of patients experiences quality of life with the EQ-5D and EQ-VAS. measure: Evaluation of patients experienced quality of life with visual analogue scale (VAS). measure: Evaluation of patients experienced treatment burden with the questionnaire Multimorbidity treatment burden questionnaire (MTBQ). measure: Evaluation of patients experienced medication burden with visual analogue scale (VAS). measure: Patient readmission 30 days after hospital discharge measure: Patient contact to the ward 30 days after hospital discharge sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Sygehus Sønderjylland city: Aabenraa state: Southern Denmark zip: 6200 country: Denmark lat: 55.04434 lon: 9.41741 hasResults: False
nctId: NCT06383351 id: BQ001 briefTitle: Patients' Illness Perception of Peri-implant Diseases. A Cross-sectional Study overallStatus: RECRUITING date: 2024-04-16 date: 2024-05 date: 2024-05 date: 2024-04-25 date: 2024-04-25 name: University of Siena class: OTHER briefSummary: Despite extensive research on periodontitis, little attention has been given to the symptoms and perception of peri-implant diseases and their impact on oral health-related quality of life. The study aims to assess patient perception of these diseases and their impact on quality of life through a cross-sectional observational study. Patients will be recruited from the Unit of Periodontics at "Le Scotte" University Hospital and will undergo diagnosis followed by questionnaire assessments. No follow-up visits are planned, and validated questionnaires will be administered to evaluate perception and impact on quality of life. Study procedures will include recording biometric peri-implant parameters and administering questionnaires such as the Brief Illness Perception Questionnaire (BIPQ) and Oral Health Impact Profile-14 (OHIP-14). conditions: Peri-implant Mucositis conditions: Perception conditions: Survey conditions: Questionnaires conditions: Peri-Implantitis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 150 type: ESTIMATED name: Questionnaire measure: Assessment of patient's perception of their peri-implant disease through the Brief Illness Perception Questionnaire (Brief IPQ) measure: Assessment of peri-implant disease's impact on the oral health-related quality of life through the Oral Health Impact Profile 14. sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: AOUS status: RECRUITING city: Siena zip: 53100 country: Italy name: Nicola Discepoli role: CONTACT phone: 3395256148 email: nicola.discepoli2@unisi.it lat: 43.31822 lon: 11.33064 hasResults: False
nctId: NCT06383338 id: PEGASUS briefTitle: A Study Investigating the Change in Metabolism Phenotype in Paediatric, Adolescent & Young Adults With Hodgkin or Non-Hodgkin Lymphoma. acronym: PEGASUS overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2025-05 date: 2026-05 date: 2024-04-25 date: 2024-04-25 name: Murdoch Childrens Research Institute class: OTHER briefSummary: PEGASUS aims to test acceptability and feasibility of studying phenoconversion (the change in metabolism phenotype) using probe medications in a paediatric oncology patient population. The study will be conducted in patients (6-25 years of age) with Hodgkin lymphoma or non-Hodgkin lymphoma as exemplar cohort, but with the understanding that cancer-directed and supportive care medicines of the CYP3A4, CYP2C19, and CYP2D6 metabolic pathways are commonly utilised for the treatment of many paediatric, adolescent, young adult, and adult cancers.
The acceptability and feasibility of this study will inform future studies in phenoconversion within the paediatric cancer population to direct more personalised precision medicine. conditions: Hodgkin Lymphoma conditions: Non Hodgkin Lymphoma studyType: INTERVENTIONAL phases: PHASE1 allocation: NON_RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: BASIC_SCIENCE masking: NONE count: 10 type: ESTIMATED name: Omeprazole name: Dextromethorphan measure: Proportion of patients who consent to study and complete baseline and at least two longitudinal timepoints with successful measurement of probe drug MR (Metabolic ratio) measure: Percentage of participants completing all required longitudinal blood sampling measure: Proportion of participants with successful detection of probe drug overall and at each sampling timepoint measure: Proportion of participants where phenotype can be classified according to MR overall at each sampling timepoint measure: The level of acceptability of participation in pharmacogenomic & phenoconversion testing using the PEGASUS specific survey tool (based on the Theoretical Framework of Acceptability [TFA]) measure: Percentage of participants experiencing an adverse event (AE) during probe drug administration measure: Incidence of genotype and phenotype mismatch, overall and across longitudinal timepoints measure: Proportion of participants with disease staging and biomarkers of extent of disease measure: Proportion of participants with a systemic inflammatory state measure: Proportion of participants taking medications involving the CYP P450 pathway measure: Participant demographic information measure: Proportion of participants with other environmental factors measure: Longitudinal inflammatory profile of participants with Hodgkin or non-Hodgkin Lymphoma as measured by a panel including serum levels of procalcitonin, c-reactive protein and cytokine analysis. sex: ALL minimumAge: 6 Years maximumAge: 25 Years stdAges: CHILD stdAges: ADULT facility: Peter MacCallum Cancer Centre city: Melbourne state: Victoria zip: 3000 country: Australia name: Marliese Alexander, Doctor of Philosophy role: CONTACT lat: -37.814 lon: 144.96332 hasResults: False
nctId: NCT06383325 id: Livertoxcicity in AL briefTitle: Livertoxcicity in Acute Leukemia Patients During Chemotherapy Treatment overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-05-01 date: 2025-08-01 date: 2024-04-25 date: 2024-04-25 name: Assiut University class: OTHER briefSummary: Detection of hepatotoxcicity in acute leukemia and study the outcome of acute leukemia patients that suffer from hepatic toxiciyt conditions: Liver Toxicity, Chemically-Induced studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 70 type: ESTIMATED name: Chemotherapy measure: Detection of hepatotoxcicity in acute leukemia during chemotherapy treatment sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06383312 id: E-10840098-772.02-4248 briefTitle: Magnetic Reflexologic Insoles for Primary Dysmenorrhea overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2024-08 date: 2024-09 date: 2024-04-25 date: 2024-04-25 name: Istanbul Medipol University Hospital class: OTHER briefSummary: In the study, easy-to-access and easy-to-use reflexologic magnetic insoles were used in women with primary dysmenorrhea who did not want to receive medical treatment; In addition to reducing symptoms such as pain, nausea, dizziness, fainting, vomiting, weakness, constipation/acute gastroenteritis, it is aimed to increase individuals' participation in daily life activities and increase their quality of life by increasing their emotional state. conditions: Primary Dysmenorrhea studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: two groups; treatment group and sham group primaryPurpose: TREATMENT masking: NONE count: 60 type: ESTIMATED name: Reflexologic Magnetic Insole Group name: Orthopedic Insole Group measure: McGill Pain Questionnaire-Short Form: measure: Menstruation Attitude Questionnaire measure: Menstruation Symptom Questionnaire measure: Visual Analogue Scale (VAS) sex: FEMALE minimumAge: 18 Years maximumAge: 30 Years stdAges: ADULT facility: Istanbul Medipol University city: Istanbul zip: 34815 country: Turkey lat: 41.01384 lon: 28.94966 hasResults: False
nctId: NCT06383299 id: AnkaraYbuMNC briefTitle: The Validity and Reliability Study of Turkish Version of Calgary Sleep Apnea Quality of Life Index overallStatus: COMPLETED date: 2021-01-01 date: 2021-07-01 date: 2021-08-01 date: 2024-04-25 date: 2024-04-25 name: Ankara Yildirim Beyazıt University class: OTHER briefSummary: The aim of this study is to investigate its validity and reliability of the questionarre whose original English name was "Calgary Sleep Apnea Quality of Life Index" which we plan to translate into Turkish as Sleep Apnea Quality of Life Index. conditions: Obstruvtive Sleep Apnea Syndrome (OSAS) studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: CROSS_SECTIONAL count: 60 type: ACTUAL measure: Calgary Sleep Apnea Quality of Life İndex (C-SAQLI) measure: Short Form 36 measure: Epworth Sleepiness Scale sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ankara Yildirim Beyazıt University city: Ankara country: Turkey lat: 39.91987 lon: 32.85427 hasResults: False
nctId: NCT06383286 id: AnkaraYBUfby briefTitle: The Relationship Between Physical Activity Levels and Anxiety, Depression, Stress of Disabled Athletes overallStatus: COMPLETED date: 2020-12-01 date: 2021-03-01 date: 2022-03-01 date: 2024-04-25 date: 2024-04-25 name: Ankara Yildirim Beyazıt University class: OTHER briefSummary: It is aimed to investigate the relationship between anxiety, depression, stress and physical activities of disabled athletes prepared for the paralympic games to be held in Tokyo in 2021, 3 times in total at 2-3 months intervals, and to determine the change over time conditions: Paralympic Athletes studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 56 type: ACTUAL measure: State-Trait Anxiety Inventory (STAI) measure: The Center for Epidemiological Studies Depression Scale (CES-D) measure: Fatigue Severity Scale measure: International Physical Activity Questionnaire short form measure: Perceived Stress Scale (PSS-14) sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Ankara Yıldırım Beyazıt Univercity city: Ankara country: Turkey lat: 39.91987 lon: 32.85427 hasResults: False
nctId: NCT06383273 id: MELT-3-001 briefTitle: A Study to Evaluate Efficacy and Safety of MELT-300 for Procedural Sedation in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR) overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2024-12 date: 2025-01 date: 2024-04-25 date: 2024-04-25 name: Melt Pharmaceuticals class: INDUSTRY name: MedTrials Incorporated name: Evolution Research Group name: Catalent name: Pharmalex briefSummary: The goal of this clinical trial is to learn if MELT-300 works on procedural sedation in adult participants undergoing cataract extraction with lens replacement (CELR). It will also learn about the safety of MELT-300. Researchers will compare MELT-300 to a placebo (a look-alike substance that contains no drug) to see if MELT-300 works on procedural sedation in adult participants undergoing CELR. Researchers will also include a comparator SL midazolam to confirm the benefit of inclusion of ketamine in the combined drug product.
The effectiveness of MELT-300 will be performed after study medication is administered before surgery, in the course of surgery, and postoperative on Day 1 (end of surgery defined as just prior to drape removal). The safety of MELT-300 will be performed at baseline, in the course of surgery, postoperatively on Day 1, and on Day 3 ± 1 day post dose of study medication. conditions: Cataract studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multi-Center Study primaryPurpose: TREATMENT masking: QUADRUPLE maskingDescription: Double-masked whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 486 type: ESTIMATED name: MELT-300 sublingual tablet name: Midalozam sublingual tablet name: Placebo sublingual tablet measure: Percentage of Participants Achieving Successful Procedural Sedation measure: Percentage of Participants Requiring Rescue Sedation Medication measure: Percentage of Participants Achieving Preoperative Procedural Sedation Without Need For Rescue Sedation Medication measure: Percentage of Participants Requiring Rescue Sedation Medication Preoperatively measure: Percentage of Participants Requiring Rescue Sedation Medication Intraoperatively measure: Assessment of Sedation Scores in Participants Without Requiring Rescue Sedation Medication measure: Percentage of Participants Able to Complete the Surgery measure: Percentage of Participants Able to Complete the Surgery Without Intervention (Other Than Rescue Sedation Medication) measure: Duration to Achieve Preoperative Target Sedation (RSS level 2 or 3) measure: Percentage of Participants Reporting Treatment Emergent Adverse Events (TEAEs) measure: Percentage of Participants Reporting Adverse Events Special Interest (AESIs) measure: Mean Change from Baseline in Blood Pressure (mmHg) measure: Mean Change from Baseline in Heart Rate [beats per minute (bpm)] measure: Mean Change from Baseline in Respiratory Rate (breath per minute) measure: Mean Change from Baseline in Body Temperature (degrees Fahrenheit) measure: Mean Change from Baseline in Pulse Oximetry (%) sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False